Occurrence and time course of NPS benzodiazepines in Sweden – results from intoxication cases in the STRIDA project

References

• Hollister LE, Muller-Oerlinghausen B, Rickels K, et al. Clinical uses of benzodiazepines. J Clin Psychopharmacol. 1993;13:1S–169S.
   PubMed Web of Science ®Google Scholar
• Longo LP, Johnson B. Addiction: part I. Benzodiazepines – side effects, abuse risk and alternatives. Am Fam Physician. 2000;61:2121–2128.
   PubMed Web of Science ®Google Scholar
• Dear JW, Bateman DN. Benzodiazepines. Medicine. 2016;44:145.
   Google Scholar
• Höjer J, Baehrendtz S, Gustafsson L. Benzodiazepine poisoning – experience of 702 admissions to an intensive-care unit during a 14-year period. J Intern Med. 1989;226:117–122.
   PubMed Web of Science ®Google Scholar
• EMCDDA. European Drug Report 2017: Trends and Developments. 2017. Available from: http://www.emcdda.europa.eu/system/files/publications/4541/TDAT17001ENN.pdf_en
   Google Scholar
• The European information system and database on new drugs (EDND) (login database). 2018 [cited June 2018]. Available from: http://ednd.emcdda.europa.eu
   Google Scholar
• Helander A, Beck O, Hägerkvist R, et al. Identification of novel psychoactive drug use in Sweden based on laboratory analysis – initial experiences from the STRIDA project. Scand J Clin Lab Invest. 2013;73:400–406.
   PubMed Web of Science ®Google Scholar
• Helander A, Bäckberg M, Hultén P, et al. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci Int. 2014;243:23–29.
   PubMed Web of Science ®Google Scholar
• Bäckberg M, Lindeman E, Beck O, et al. Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project. Clin Toxicol. 2015;53:46–53.
   PubMed Web of Science ®Google Scholar
• Beck O, Bäckberg M, Signell P, et al. Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats. Clin Toxicol. 2017;56:256–263.
   Web of Science ®Google Scholar
• Bäckberg M, Beck O, Helander A. Phencyclidine analog use in Sweden – intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol. 2015;53:856–864.
   PubMed Web of Science ®Google Scholar
• Pettersson Bergstrand M, Beck O, Helander A. Urine analysis of 28 designer benzodiazepines by liquid chromatography–high-resolution mass spectrometry. Clin Mass Spectrom. 2018. (accepted for publication).
   Google Scholar
• Pettersson Bergstrand M, Helander A, Hansson T, et al. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Test Anal. 2017;9:640–645.
   PubMed Web of Science ®Google Scholar
• Zherdev VP, Caccia S, Garattini S, et al. Species differences in phenazepam kinetics and metabolism. Eur J Drug Metab Pharmacokinet. 1982;7:191–196.
   PubMed Web of Science ®Google Scholar
• Moosmann B, Huppertz LM, Hutter M, et al. Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom. 2013;48:1150–1159.
   PubMed Web of Science ®Google Scholar
• Joyce JR, Bal TS, Ardrey RE, et al. The decomposition of benzodiazepines during analysis by capillary gas chromatography/mass spectrometry. Biomed Mass Spectrom. 1984;11:284–289.
   PubMedGoogle Scholar
• Starmark JE, Stålhammar D, Holmgren E. The Reaction Level Scale (RLS85). Manual and guidelines. Acta Neurochir. 1988;91:12–20.
   PubMed Web of Science ®Google Scholar
• Starmark JE, Stålhammar D, Holmgren E, et al. A comparison of the Glasgow Coma Scale and the Reaction Level Scale (RLS85). J Neurosurg. 1988;69:699–706.
   PubMed Web of Science ®Google Scholar
• Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36:205–213.
   PubMed Web of Science ®Google Scholar
• Pettersson Bergstrand M, Helander A, Beck O. Development and application of a multi-component LC–MS/MS method for determination of designer benzodiazepines in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1035:104–110.
   PubMed Web of Science ®Google Scholar
• Simonsen KW, Edvardsen HM, Thelander G, et al. Fatal poisoning in drug addicts in the Nordic countries in 2012. Forensic Sci Int. 2015;248:172–180.
   PubMed Web of Science ®Google Scholar
• Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125:8–18.
   PubMed Web of Science ®Google Scholar
• EMCDDA. European Drug Report 2018: Trends and Developments. 2018. Available from: http://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT18001ENN_PDF.pdf
   Google Scholar
• Rafstedt K, Hultén P, Brusin K. Phenazepam as a drug of abuse – high frequency of prolonged symptoms. Presented at the 29th International Congress of the European Association of Poison Centers and Clinical Toxicologists in Stockholm. Clin Toxicol. 2009;47:436.
   Google Scholar
• The Medical Products Agency’s list of provisions on narcotics 2011. [Läkemedelsverkets föreskrifter om förteckningar över narkotika (LVFS 2011:10/HSLF-FS 2018:9)]. Available from: https://lakemedelsverket.se/upload/lvfs/konsoliderade/LVFS_2011_10_konsoliderad_tom_HSLF-FS_2018_9.pdf (in Swedish).
   Google Scholar
• Flashback. 2018 [cited June 2018]. Available from: https://www.flashback.org
   Google Scholar
• Swedish National Forensic Centre (NFC). 2018. [personal communication]
   Google Scholar
• Helander A, Bäckberg M. New Psychoactive Substances (NPS) – the Hydra monster of recreational drugs. Clin Toxicol. 2017;55:1–3.
   PubMed Web of Science ®Google Scholar
• Andersson M, Kjellgren A. The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. Nord Stud Alcohol Dr. 2017;34:217–229.
   Web of Science ®Google Scholar
• Huppertz LM, Bisel P, Westphal F, et al. Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. Forensic Toxicol. 2015;33:388–395.
   Web of Science ®Google Scholar
• Huppertz LM, Moosmann B, Auwarter V. Flubromazolam – basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal. 2018;10:206–211.
   PubMed Web of Science ®Google Scholar
• Łukasik-Głębocka M, Sommerfeld K, Teżyk A, et al. Flubromazolam – a new life-threatening designer benzodiazepine. Clin Toxicol. 2016;54:66–68.
   PubMed Web of Science ®Google Scholar
• EMCDDA. Perspectives on drugs – the misuse of benzodiazepines among high-risk opioid users in Europe. 2015. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_239694_EN_Misuse%20of%20benzos_POD2015.pdf
   Google Scholar
• Manchester KR, Lomas EC, Waters L, et al. The emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug Test Anal. 2018;10:392–353.
   PubMed Web of Science ®Google Scholar
• Penninga EI, Graudal N, Ladekarl MB, et al. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication – a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol Toxicol. 2016;118:37–44.
   PubMed Web of Science ®Google Scholar
• Katselou M, Papoutsis I, Nikolaou P, et al. Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam. Forensic Toxicol. 2017;35:1–10.
   PubMed Web of Science ®Google Scholar
• Moosmann B, Bisel P, Franz F, et al. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines – an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam. J Mass Spectrom. 2016;51:1080–1089.
   PubMed Web of Science ®Google Scholar
• Schukin SI, Zinkovsky VG, Zhuk OV. Elimination kinetics of the novel prodrug cinazepam possessing psychotropic activity in mice. Pharmacol Rep. 2011;63:1093–1100.
   PubMed Web of Science ®Google Scholar
• Moosmann B, Bisel P, Auwarter V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal. 2014;6:757–763.
   PubMed Web of Science ®Google Scholar
• Meyer MR, Bergstrand MP, Helander A, et al. Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography–high-resolution mass spectrometry for drug testing purposes. Anal Bioanal Chem. 2016;408:3571–3591.
   PubMed Web of Science ®Google Scholar